Results 241 to 250 of about 69,426 (314)
Guillain-Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study. [PDF]
Cabon J +6 more
europepmc +1 more source
ABSTRACT Aims The use of glucagon‐like peptide‐1 (GLP1) analogues has increased due to benefits in glycaemic control, weight loss, and cardiorenal protection. However, concerns persist regarding their potential link to pancreatitis. We assessed this link in high‐risk patients with a history of pancreatitis or elevated lipase enzyme.
Bronya Calvarysky +6 more
wiley +1 more source
Management of Tinea Capitis in children under 10 kg : Results from a French multicentre study
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page e146-e150, February 2026.
A. Cornillault +39 more
wiley +1 more source
Exploring Stakeholder Perceptions and Experience of Biosimilar Insulin Switching: A Scoping Review
This scoping review has systematically mapped the existing literature on stakeholder perceptions and experience of biosimilar insulin switches. It shows that there is a lack of high‐quality context‐specific research in this area, and more needs to be done to understand this topic. ABSTRACT Background The option to switch patients to more cost‐effective
Ben Hindley +4 more
wiley +1 more source
The role of MedDRA in global pharmacovigilance and public health during COVID-19: pandemic preparedness and response. [PDF]
O'Hare B, Ibrahim H, Revelle P.
europepmc +1 more source
Anti‐Neuroinflammation Activity of Essential Oils and Fatty Acids
Neuroinflammation plays a pivotal role in the pathogenesis of neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). Current pharmacological interventions, such as NSAIDs and corticosteroids, are limited by systemic toxicity and insufficient efficacy in targeting chronic neuroinflammatory processes.
Zelong Jin +5 more
wiley +1 more source
Correction: Leveraging real-world data for safety signal detection and risk management in pre- and post-market settings. [PDF]
Gavin KM, Sundermann ML, Wieland A.
europepmc +1 more source
Sublingual Immunotherapy: Insights into Clinical Benefits and Safety Profile. [PDF]
Castellana E, Chiappetta MR.
europepmc +1 more source

